证券代码：600851/900917 证券简称：海欣股份/海欣 B 股 公告编号：2024-024 上海海欣集团股份有限公司 关于参加上海辖区上市公司 2024 年投资者 网上集体接待日暨中报业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可提前通过公司邮箱 600851@haixin.com 进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 上海海欣集团股份有限公司（以下简称"公司"）已于 2024 年 8 月 24 日发布公 司 2024 年半年度报告。为进一步加强与投资者的互动交流，公司将参加由上海上市 公司协会与深圳市全景网络有限公司联合举办的"2024 年上海辖区上市公司投资者集 体接待日暨中报业绩说明会"，现将相关事项公告如下： 一、 说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2024 年半年度的经营成果及 财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资 者普遍关注的问题进行回答。 1 会议召开时间：2024 年 9 月 ...

Company Profile and Key Financial Indicators [Company Information](index=4&type=section&id=Company%20Information) Shanghai Haixin Group Co, Ltd is a listed company engaged in pharmaceuticals, property leasing, textiles, financial investment, and commodity trading - Basic company information includes its Chinese name “上海海欣集团股份有限公司”, A-share ticker “海欣股份”, B-share ticker “海欣B股”, and legal representative, Fei Minhua[12](index=12&type=chunk)[16](index=16&type=chunk) [Key Accounting Data and Financial Indicators](index=5&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) Revenue fell 34.98% due to the deconsolidation of Haixin Pharmaceutical and reduced trade, while net cash flow from operations surged 1687.11% from lower tax payments 2024 H1 Key Accounting Data | Key Accounting Data | Current Period (Jan-Jun) (Yuan) | Prior Year Period (Yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 406,499,814.08 | 625,159,485.96 | -34.98 | | Net Profit Attributable to Shareholders | 101,781,616.57 | 101,676,991.04 | 0.10 | | Net Profit Attributable to Shareholders (Non-recurring items deducted) | 99,477,853.24 | 104,421,712.71 | -4.73 | | Net Cash Flow from Operating Activities | 66,627,801.39 | 3,728,237.70 | 1,687.11 | | **Asset Status** | **End of Current Period** | **End of Prior Year** | **Change from Prior Year-End (%)** | | Net Assets Attributable to Shareholders | 3,886,419,387.36 | 3,965,055,449.29 | -1.98 | | Total Assets | 4,870,678,774.69 | 4,910,625,159.28 | -0.81 | 2024 H1 Key Financial Indicators | Key Financial Indicator | Current Period (Jan-Jun) | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (Yuan/Share) | 0.0843 | 0.0842 | 0.12% | | Weighted Average Return on Equity (%) | 2.5344 | 2.6108 | Decrease of 0.0764 percentage points | - The decline in operating revenue was mainly due to the deconsolidation of Haixin Pharmaceutical (a decrease of 80.27 million Yuan) and a reduction in commodity trading revenue (77.18 million Yuan)[19](index=19&type=chunk) - The significant increase in net cash flow from operating activities was primarily due to a **56.29 million Yuan reduction** in various tax payments[20](index=20&type=chunk) [Non-recurring Profit and Loss Items and Amounts](index=6&type=section&id=Non-recurring%20Profit%20and%20Loss%20Items%20and%20Amounts) Non-recurring profit and loss for the period totaled 2.30 million Yuan, mainly from fair value changes and disposals of financial assets and liabilities Non-recurring Profit and Loss Items | Item | Amount (Yuan) | | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | -37,965.91 | | Government Grants Recognized in Current Profit or Loss | 891,877.80 | | Fair Value Changes and Disposal Gains/Losses on Financial Assets/Liabilities | 2,599,130.54 | | Other Non-operating Income and Expenses | -299,104.54 | | Other Items Meeting the Definition of Non-recurring P&L | 216,686.29 | | **Total** | **2,303,763.33** | Management Discussion and Analysis [Report on the Company's Industry and Main Business during the Reporting Period](index=6&type=section&id=Report%20on%20the%20Company's%20Industry%20and%20Main%20Business%20during%20the%20Reporting%20Period) The company operates across five segments: pharmaceuticals, property management, textiles, financial investment, and commodity trading - The company's main business segments include: - **Pharmaceuticals**: Primarily focused on chemical drug production and sales - **Industrial Plant and Property Leasing**: Manages and leases existing properties - **Textiles**: Engaged in the R&D, production, and sale of plush fabrics and apparel - **Financials**: Holds equity stakes in Changjiang Securities and Changxin Asset Management - **Commodity Trading**: Participates in upstream and downstream supply chain procurement and sales[25](index=25&type=chunk) [Discussion and Analysis of Operations](index=7&type=section&id=Discussion%20and%20Analysis%20of%20Operations) In H1 2024, the company achieved revenue of 407 million Yuan (-34.98% YoY) and net profit of 102 million Yuan (+0.10% YoY) amid a complex environment - **Pharmaceuticals Segment**: Holding pharmaceutical manufacturing companies achieved a combined operating revenue of **236 million Yuan**, down 15.00% YoY, and a combined net profit attributable to the parent of **10.57 million Yuan**, down 5.29% YoY[27](index=27&type=chunk)[28](index=28&type=chunk) - **Property Segment**: Maintained an occupancy rate of around **90%** despite market downturns, generating self-operated leasing income of **41.99 million Yuan** and a net operating profit of **25.83 million Yuan**, up 2.63% YoY[29](index=29&type=chunk)[30](index=30&type=chunk) - **Textiles Segment**: Continued its contraction and adjustment, with revenue of **63.49 million Yuan** (-25.29% YoY), but achieved a turnaround in net profit attributable to the parent, realizing a profit of **44,900 Yuan**[31](index=31&type=chunk) [Key Operations during the Reporting Period](index=8&type=section&id=Key%20Operations%20during%20the%20Reporting%20Period) Significant financial metric changes occurred, including decreased revenue and costs, a 78.60% drop in finance costs, and a 1687.11% surge in operating cash flow Analysis of Key Items in Financial Statements | Item | Current Period (Yuan) | Prior Year Period (Yuan) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 406,499,814.08 | 625,159,485.96 | -34.98 | Deconsolidation of Haixin Pharmaceutical and reduced commodity trading revenue | | Operating Costs | 169,159,793.18 | 332,617,406.22 | -49.14 | Deconsolidation of Haixin Pharmaceutical and reduced commodity trading costs | | Finance Costs | -4,279,137.94 | -2,395,882.98 | -78.60 | Reduced interest expense and increased foreign exchange gains | | Net Cash Flow from Operating Activities | 66,627,801.39 | 3,728,237.70 | 1,687.11 | Decrease in various tax payments | | Net Cash Flow from Investing Activities | -107,248,544.75 | 85,189,284.71 | -225.89 | Decrease in investment redemptions (wealth management products) | | Net Cash Flow from Financing Activities | -20,484,169.35 | -1,622,224.39 | 1,162.72 | Reduced borrowing by Nanjing Plush | Performance of Major Subsidiaries and Investees | Company Name | Business Nature | Net Profit (CNY 10,000) | Investment Income (CNY 10,000) | % of Company's Net Profit | | :--- | :--- | :--- | :--- | :--- | | **Holding Subsidiaries** | | | | | | Jiangxi Gannan Haixin Pharmaceutical | Pharmaceuticals | 2,019.15 | - | - | | Xi'an Haixin Pharmaceutical | Pharmaceuticals | -346.92 | - | - | | Nanjing Haixin Lining Plush | Textiles | 290.22 | - | - | | **Investee Companies** | | | | | | Changjiang Securities | Financials | - | 2,978.40 | 29.26% | | Changxin Asset Management | Financials | - | 1,720.97 | 16.91% | | Jiangsu Suzhong Pharmaceutical Group | Pharmaceuticals | - | 1,271.17 | 12.49% | | Jiangsu Suzhong Health Technology | Health Services | - | 1,315.72 | 12.93% | - The company faces key risks including market competition, policy changes in healthcare and finance, technological iteration, environmental protection, and quality control[46](index=46&type=chunk)[47](index=47&type=chunk)[48](index=48&type=chunk)[50](index=50&type=chunk)[51](index=51&type=chunk) Corporate Governance [Summary of Shareholders' Meetings](index=12&type=section&id=Summary%20of%20Shareholders'%20Meetings) The 2023 Annual General Meeting was held on June 20, 2024, approving the annual report, profit distribution plan, and amendments to the Articles of Association - The 2023 Annual General Meeting approved multiple resolutions, including the "Company's 2023 Annual Report," the "2023 Profit Distribution Plan," and the "Resolution on Amending the <Articles of Association> and Related Policies"[56](index=56&type=chunk)[58](index=58&type=chunk) [Changes in the Company's Directors, Supervisors, and Senior Management](index=13&type=section&id=Changes%20in%20the%20Company's%20Directors,%20Supervisors,%20and%20Senior%20Management) Significant leadership changes occurred with the election of the 11th Board of Directors and Supervisory Committee and the appointment of new senior management - On July 15, 2024, the company completed its leadership transition, electing the 11th Board of Directors and Supervisory Committee[60](index=60&type=chunk) - On the same day, the 11th Board of Directors appointed Mr. Ren Xiaowei as President and appointed or re-appointed several Vice Presidents, a CFO, and a Board Secretary[60](index=60&type=chunk) Environmental and Social Responsibility [Environmental Information](index=14&type=section&id=Environmental%20Information) Three subsidiaries are designated as key pollutant-discharging units, with all facilities operating normally and no environmental penalties received during the period - The company's subsidiaries Gannan Haixin, Shaanxi Pharmaceutical, and Baoding Plush are listed as **key pollutant-discharging units**[65](index=65&type=chunk) - Each key unit is equipped with corresponding wastewater and exhaust gas treatment facilities, which are operating normally to ensure compliant emissions[68](index=68&typechunk)[69](index=69&type=chunk) - All three subsidiaries hold valid pollutant discharge permits and have formulated emergency response plans for environmental incidents[70](index=70&type=chunk)[71](index=71&type=chunk) Significant Matters [Fulfillment of Commitments](index=19&type=section&id=Fulfillment%20of%20Commitments) Historical commitments related to share reform and refinancing, including share sale disclosures and avoiding horizontal competition, were strictly fulfilled - Company shareholders continued to fulfill commitments made during share reform and refinancing regarding share sale disclosures and the avoidance of horizontal competition[76](index=76&type=chunk) [Significant Guarantees](index=21&type=section&id=Significant%20Guarantees) The company had no external guarantees; guarantees for subsidiaries totaled 13.75 million Yuan, representing 0.35% of the company's net assets Summary of Guarantees | Guarantee Category | Amount Incurred (CNY 10,000) | Balance at Period-End (CNY 10,000) | | :--- | :--- | :--- | | External Guarantees | 0 | 0 | | Guarantees for Subsidiaries | 1,375 | 1,375 | | **Total Guarantees** | **1,375** | **1,375** | | Total Guarantees as % of Net Assets | - | 0.35% | Share Capital Changes and Shareholder Information [Changes in Share Capital](index=22&type=section&id=Changes%20in%20Share%20Capital) The company's total number of shares and share capital structure remained unchanged during the reporting period - During the reporting period, the company's total number of shares and share capital structure did not change[83](index=83&type=chunk) [Shareholder Information](index=22&type=section&id=Shareholder%20Information) As of the period-end, the company had 60,807 common shareholders, with the top two shareholders and their concerted parties holding a combined 14.98% - As of the period-end, the company had **60,807 common shareholders**, comprising 30,887 A-share holders and 29,920 B-share holders[84](index=84&type=chunk) Top Ten Shareholders | Shareholder Name | Shares Held at Period-End | Percentage (%) | | :--- | :--- | :--- | | 1. Hunan Ningrui Investment Partnership (LP) | 141,528,801 | 11.73 | | 2. Shanghai Songjiang Dongjing Industrial Corp | 82,082,000 | 6.80 | | 3. Jiaxing Qingxin Zhengmao Equity Investment Partnership | 60,000,000 | 4.97 | | 4. Shanghai Toys Import & Export Co, Ltd | 39,300,000 | 3.26 | | 5. Hunan Caixin Economic Investment Co, Ltd | 39,288,210 | 3.25 | - Shareholder relationship disclosure: Hunan Ningrui Investment Partnership (LP) and Hunan Caixin Economic Investment Co, Ltd are **concerted parties**[87](index=87&type=chunk) Financial Report [Financial Statements](index=25&type=section&id=Financial%20Statements) The unaudited H1 2024 report shows total assets of 4.87 billion Yuan, net profit of 102 million Yuan, and operating cash flow of 66.63 million Yuan - This semi-annual report is **unaudited**[6](index=6&type=chunk) Consolidated Financial Statement Core Data (As of June 30, 2024 / For Jan-Jun 2024) | Indicator | Amount (CNY) | | :--- | :--- | | **Balance Sheet:** | | | Total Assets | 4.87 billion | | Total Liabilities | 0.82 billion | | Equity Attributable to Parent Company | 3.89 billion | | **Income Statement:** | | | Operating Revenue | 406 million | | Net Profit Attributable to Parent Company | 102 million | | Basic Earnings Per Share | 0.0843 Yuan | | **Cash Flow Statement:** | | | Net Cash Flow from Operating Activities | 66.63 million | | Net Cash Flow from Investing Activities | -107.25 million | | Net Cash Flow from Financing Activities | -20.48 million | [Notes to Consolidated Financial Statement Items](index=74&type=section&id=Notes%20to%20Consolidated%20Financial%20Statement%20Items) Notes detail account balances, including 1.21 billion Yuan in long-term equity investments and 844 million Yuan in investment properties at fair value - The top five accounts receivable balances account for **28.73% of the total**, with significant bad debt provisions made for receivables from Nanjing Hongli Trading and Dumont (Shanghai) Trading[308](index=308&type=chunk) - Long-term equity investments primarily include investments in joint venture Shanghai Jinxin United Development (book value **564 million Yuan**) and associates Changxin Asset Management (**392 million Yuan**), Suzhong Pharmaceutical (**111 million Yuan**), and Suzhong Health Technology (**131 million Yuan**)[336](index=336&type=chunk) - Other equity instrument investments mainly consist of the investment in Changjiang Securities, with a period-end book value of **1.20 billion Yuan**[338](index=338&type=chunk) - Construction in progress is mainly for the Haixin Intelligent Industrial Park project, with a book balance of **202 million Yuan** and a budget completion rate of approximately **80.59%**[351](index=351&type=chunk)[354](index=354&type=chunk) [Segment Information](index=138&type=section&id=Segment%20Information) The company reports five segments, with the medical segment being the largest revenue contributor and the investment segment the most profitable in H1 2024 H1 2024 Financial Information by Segment (Unit: Yuan) | Item | Investment (Seg 1) | Textiles (Seg 2) | Medical (Seg 3) | Trading (Seg 4) | Industrial Park (Seg 5) | | :--- | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 3,153,172.41 | 63,486,257.77 | 235,908,582.24 | 63,499,778.76 | 47,826,490.57 | | Net Profit | 101,498,815.69 | -516,490.03 | 15,617,869.77 | 1,084,507.71 | 11,105,046.10 |

Financial Performance - The company's operating revenue for the year 2023 reached CNY 4,988,253.83, an increase from CNY 3,355,622.30 in 2022, representing a growth of approximately 48.6%[31] - The net profit for 2023 was CNY 99,119,499.26, compared to CNY 166,240,576.08 in 2022, indicating a decrease of about 40.3%[31] - Basic earnings per share for 2023 were CNY 0.1376, slightly up from CNY 0.1359 in 2022[30] - The company reported investment income of CNY 162,678,613.50 for 2023, down from CNY 214,660,127.20 in 2022, a decline of approximately 24.2%[31] - The total operating profit for 2023 was CNY 94,911,546.44, a decrease from CNY 157,671,625.00 in the previous year, reflecting a decline of about 39.8%[31] - The total profit amounted to ¥207,181,178.48, a decrease from ¥230,329,731.65 in the previous period, reflecting a decline of approximately 10%[34] - Net profit for the period was ¥192,107,136.51, compared to ¥198,382,453.82 in the prior year, indicating a decrease of about 3%[34] - The net profit attributable to shareholders of the parent company was ¥166,030,649.74, slightly up from ¥164,056,061.10, showing an increase of approximately 1.2%[34] - The total comprehensive income for the period was ¥202,115,102.45, contrasting with a loss of ¥206,921,483.57 in the previous period[34] - The total comprehensive income for the year was 176.04 million yuan, with a net profit distribution of -64.23 million yuan[70] Cash Flow and Assets - The cash flow from operating activities was 1,214.46 million yuan, down from 1,547.99 million yuan in the previous year[65] - Cash and cash equivalents increased to ¥509.55 million from ¥420.29 million, representing a growth of approximately 21% year-over-year[174] - Total current assets decreased from 1,087,716,787.09 to 993,987,824.74, a decline of approximately 8.6%[178] - Long-term equity investments increased from 1,127,034,374.09 to 1,181,061,183.99, representing a growth of about 4.8%[178] - Total liabilities decreased from 911,215,769.39 to 775,286,878.90, a reduction of approximately 14.9%[180] - Total owner's equity increased from 4,018,848,320.64 to 4,135,338,280.38, reflecting an increase of about 2.9%[180] - Cash and cash equivalents rose from 228,011,028.77 to 290,632,320.87, an increase of approximately 27.5%[186] - Total assets decreased slightly from 4,930,064,090.03 to 4,910,625,159.28, a decrease of about 0.4%[180] Expenses and Costs - Total operating costs for 2023 were $1,116,082,358.77, down about 21.3% from $1,416,807,804.41 in 2022[190] - Operating profit for 2023 was $210,512,398.60, a decline of around 8.4% from $229,889,547.81 in 2022[190] - Research and development expenses increased to $23,109,998.20 in 2023, compared to $22,672,328.29 in 2022, reflecting a growth of approximately 1.9%[190] - Sales expenses decreased to $327,042,249.54 in 2023, a reduction of about 25% from $434,867,383.46 in 2022[190] - Management expenses were $123,438,537.06 in 2023, down from $145,232,641.24 in 2022, indicating a decrease of approximately 15%[190] - Tax expenses for 2023 were $17,989,872.04, significantly lower than $44,298,106.17 in 2022, marking a decrease of about 59.5%[190] - Other income for 2023 was $2,838,674.31, down from $6,669,192.60 in 2022, reflecting a decline of approximately 57.5%[190] - Financial expenses showed a net income of -$7,073,168.60 in 2023, compared to -$5,437,487.47 in 2022, indicating an increase in financial costs[190] Shareholder Information - The proposed cash dividend is ¥0.65 per 10 shares, totaling ¥78,458,684.98, which is 47.26% of the net profit attributable to shareholders[56] - There were no significant changes in the shareholding structure during the reporting period, with the largest shareholder holding 11.73% of the shares[20] - The company reported no guarantees provided to external parties, while guarantees to subsidiaries totaled ¥1,375.00, representing 0.35% of the company's net assets[35] - The company has not incurred any new guarantees during the reporting period, maintaining a stable financial position[35] Strategic Initiatives - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year[34] - The company is focusing on enhancing its corporate culture and party building to boost team spirit and business development[60] - The company is committed to improving risk prevention effectiveness through optimized internal control systems[60] - The company emphasizes the importance of innovation in technology, products, and market strategies to remain competitive in the increasingly challenging pharmaceutical industry[98] - The company is actively engaged in research and development to enhance product quality and efficacy, driven by government policies supporting pharmaceutical innovation[98] - The company has a commitment to expanding its market presence and exploring new investment opportunities in line with national industrial policies[74] - Future outlook includes plans for market expansion and potential acquisitions to enhance growth opportunities[151] - The company is exploring strategic partnerships to leverage synergies and enhance market presence[151] Compliance and Governance - The company has strengthened its internal management mechanisms and governance levels in compliance with legal regulations[60] - The financial report was approved for publication on April 18, 2024, indicating the company's adherence to regulatory requirements[74] - The company has maintained its accounting policies consistent with the previous year, ensuring comparability in financial reporting[110] - The financial statements have been prepared in accordance with applicable accounting standards, ensuring transparency and accuracy[110]

Financial Performance - Q3 2023 revenue was CNY 321,539,166.53, a decrease of 22.03% year-over-year[3] - Net profit attributable to shareholders was CNY 24,262,874.13, down 46.13% compared to the same period last year[3] - Basic earnings per share decreased by 46.11% to CNY 0.0201[4] - Total operating revenue for the first three quarters of 2023 was CNY 946,698,652.49, a decrease of 9.8% compared to CNY 1,048,902,061.80 in the same period of 2022[17] - Net profit for the first three quarters of 2023 was CNY 131,618,732.09, a decline of 27.6% from CNY 181,714,625.37 in 2022[18] - Earnings per share for the third quarter were CNY 0.1043, down from CNY 0.1410 in the previous year[19] Assets and Liabilities - Total assets increased by 2.90% to CNY 5,072,793,296.77 compared to the end of the previous year[4] - As of September 30, 2023, the total assets of the company amounted to CNY 5,072,793,296.77, an increase from CNY 4,930,064,090.03 at the end of 2022, representing a growth of approximately 2.88%[13] - The total liabilities decreased slightly to CNY 911,120,500.25 from CNY 911,215,769.39, indicating a marginal reduction of approximately 0.01%[15] - The total current liabilities decreased to CNY 441,054,176.94 from CNY 472,471,150.87, showing a decline of approximately 6.64%[15] - The company's total equity attributable to shareholders increased to CNY 4,011,605,322.87 from CNY 3,843,579,153.36, representing a growth of 4.4%[16] Cash Flow - Cash flow from operating activities was CNY 31,746,564.80, an increase of 7.21% year-over-year[3] - Operating cash flow for the first nine months of 2023 was CNY 35,474,802.50, a decrease from CNY 40,002,254.43 in the same period of 2022, reflecting a decline of approximately 3.3%[24] - Total cash inflow from operating activities was CNY 1,024,531,608.07, compared to CNY 1,154,783,645.74 in the previous year, indicating a decrease of about 11.2%[24] - Cash inflow from investment activities increased to CNY 864,504,202.52 from CNY 737,641,448.98, representing a growth of approximately 17.2%[25] - Net cash flow from investment activities was CNY 146,844,967.83, up from CNY 82,160,513.41, showing an increase of about 78.8%[25] - Cash inflow from financing activities totaled CNY 71,079,404.26, compared to CNY 64,679,105.50, marking an increase of approximately 9.3%[25] - Net cash flow from financing activities was negative at CNY -52,562,278.08, worsening from CNY -44,648,448.62 in the previous year[25] - The ending balance of cash and cash equivalents was CNY 551,312,552.69, up from CNY 404,489,751.26, reflecting an increase of about 36.3%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 64,114[9] - The top shareholder, Shenzhen Ningrui Investment Management Enterprise, holds 11.73% of the shares[9] Operational Insights - The company plans to focus on improving operational efficiency and exploring new market opportunities[7] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] Other Financial Metrics - The company reported a decrease in investment income from associates, contributing to the decline in net profit[7] - Investment income for the first three quarters was CNY 115,566,685.23, down from CNY 175,179,431.91, indicating a decrease of 34.0%[18] - Other comprehensive income after tax for the third quarter was CNY 94,646,632.77, a significant recovery from a loss of CNY 429,659,513.94 in the previous year[18] - The company reported a decrease in sales expenses to CNY 288,897,754.42 from CNY 372,198,510.68, a reduction of 22.5%[17] - Management expenses decreased to CNY 88,434,728.03 from CNY 100,047,385.68, reflecting a decline of 11.6%[17] - The company's accounts receivable decreased to CNY 149,941,986.02 from CNY 174,382,888.61, a reduction of about 13.96%[13] - The company's inventory decreased to CNY 79,049,664.55 from CNY 89,520,866.14, reflecting a decline of approximately 11.7%[14] - The company reported a significant increase in other receivables, rising to CNY 43,795,581.05 from CNY 35,091,523.76, an increase of approximately 24.5%[14] - Total cash outflow from investment activities was CNY 717,659,234.69, compared to CNY 655,480,935.57, representing an increase of about 9.5%[25] - Cash received from the recovery of investments was CNY 787,638,163.43, compared to CNY 625,083,307.80, indicating an increase of approximately 26%[24] - Cash received from other operating activities was CNY 61,963,637.42, significantly higher than CNY 35,306,486.61, showing an increase of approximately 75.9%[24] - Non-recurring gains and losses totaled CNY -1,508,906.34 for the current period[6]

Group 1: Meeting Details - The meeting is scheduled for September 7, 2023, from 14:00 to 16:30 [3] - The location for the meeting is the "Panorama Roadshow" website (http://rs.p5w.net) [5] - The meeting will be conducted in an interactive online format [4] Group 2: Participation and Interaction - Investors can participate by logging into the "Panorama Roadshow" website or through the WeChat public account: Panorama Finance [6] - Investors are encouraged to submit questions in advance via a QR code provided in the announcement [3] - The company will address commonly asked questions during the performance briefing [4] Group 3: Company Representatives - Key participants include Chairman Fei Minhua, Independent Director Li Zhijun, President and Secretary Ren Xiaowei, and CFO Zhu Xifeng [6] Group 4: Contact Information - For inquiries, investors can contact the Secretary Office at 021-57698031 or via email at 600851@haixin.com [7] - Post-event, details of the meeting and its main content will be available on the "Panorama Roadshow" website [7]

Financial Performance - The company's operating revenue for Q1 2023 was ¥282,592,919.46, representing a decrease of 6.66% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥26,525,288.95, down by 2.89% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 10.15% to ¥26,273,745.64[5]. - The net profit for Q1 2023 was CNY 27,014,690.72, a decrease of 7.5% compared to CNY 29,259,143.67 in Q1 2022[19]. - Operating profit for Q1 2023 was CNY 29,209,428.18, down from CNY 32,609,582.98 in the same period last year, reflecting a decline of 7.3%[19]. - The total comprehensive income for Q1 2023 was CNY 70,536,351.32, compared to a loss of CNY 215,686,395.08 in Q1 2022[20]. - The total revenue from sales of goods and services in Q1 2023 was CNY 294,546,469.52, a decrease of 15.2% from CNY 347,428,782.83 in Q1 2022[21]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥3,828,556.17, a decline of 120.05% compared to the previous year[5]. - Cash flow from operating activities showed a net outflow of CNY 3,828,556.17 in Q1 2023, compared to a net inflow of CNY 19,097,360.28 in Q1 2022[22]. - Cash flow from investing activities resulted in a net outflow of CNY 9,366,748.98 in Q1 2023, a significant decrease from a net inflow of CNY 48,276,678.66 in Q1 2022[22]. - The company's cash and cash equivalents as of March 31, 2023, were CNY 418,431,222.38, slightly down from CNY 420,285,866.49 at the end of 2022[15]. - The cash and cash equivalents at the end of Q1 2023 stood at CNY 418,431,222.38, compared to CNY 395,419,292.24 at the end of Q1 2022, reflecting an increase of 5.3%[23]. - Total assets at the end of the reporting period were ¥4,984,250,435.15, an increase of 1.10% from the end of the previous year[6]. - The total assets increased to CNY 4,984,250,435.15 from CNY 4,930,064,090.03, representing a growth of 1.1%[18]. - Total liabilities decreased to CNY 894,865,763.19 from CNY 911,215,769.39, a reduction of approximately 1.8%[17]. Shareholder Information - Basic and diluted earnings per share were both ¥0.0220, down by 2.65%[6]. - The total number of ordinary shareholders at the end of the reporting period was 68,059, with 36,051 A-shareholders and 32,008 B-shareholders[11]. - The company reported a basic and diluted earnings per share of CNY 0.0220 for Q1 2023, slightly down from CNY 0.0226 in Q1 2022[20]. Costs and Expenses - Total operating costs for Q1 2023 were CNY 274,024,708.30, down 7.6% from CNY 296,583,327.39 in Q1 2022[18]. - Research and development expenses for Q1 2023 were CNY 4,221,568.55, down from CNY 4,743,720.99 in Q1 2022, indicating a decrease of about 11%[18]. - The company incurred a tax expense of CNY 2,302,342.80 in Q1 2023, down from CNY 3,080,536.61 in Q1 2022, indicating a reduction of 25.3%[19]. - The significant decrease in cash flow was primarily due to increased tax payments, including ¥30.83 million in VAT and ¥9.72 million in land value-added tax[9]. Non-Recurring Items - The company reported non-recurring gains and losses totaling ¥251,543.31 for the period[8]. - The company reported an investment income of CNY 20,949,413.12 for Q1 2023, compared to CNY 22,970,174.34 in Q1 2022, reflecting a decline of approximately 8.8%[18]. - The company reported a significant increase in other comprehensive income, amounting to CNY 43,521,660.60 in Q1 2023, compared to a loss of CNY 244,945,538.75 in Q1 2022[19]. Accounts Receivable and Inventory - Accounts receivable decreased to CNY 147,053,109.62 from CNY 174,382,888.61, reflecting a reduction of approximately 15.7%[15]. - Inventory as of March 31, 2023, was CNY 87,473,441.31, a slight decrease from CNY 89,520,866.14 at the end of 2022[16].

Financial Performance - In 2022, the company achieved a net profit attributable to shareholders of RMB 164,056,061.10, representing a 24.20% increase compared to RMB 132,091,780.53 in 2021[6]. - The company's operating revenue for 2022 was RMB 1,440,090,739.79, a decrease of 4.71% from RMB 1,511,255,284.73 in 2021[23]. - The net cash flow from operating activities decreased by 66.51% to RMB 73,558,233.78, down from RMB 219,647,104.26 in the previous year[23]. - The basic earnings per share for 2022 increased by 24.22% to RMB 0.1359, compared to RMB 0.1094 in 2021[25]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which rose by 50.03% to RMB 155,822,289.93[23]. - The company achieved a consolidated revenue of CNY 1.44 billion in 2022, a decrease of 4.71% year-on-year[45]. - The net profit attributable to the parent company was CNY 164 million, an increase of 24.20% year-on-year[45]. - Total revenue for the year was approximately CNY 1,277.75 million, a decrease of 5.92% compared to the previous year[50]. Asset Management - The company's total assets as of the end of 2022 were RMB 4,930,064,090.03, a decrease of 7.43% from RMB 5,325,619,470.52 at the end of 2021[23]. - The company’s net assets attributable to shareholders decreased by 6.90% to RMB 3,843,579,153.36 at the end of 2022, down from RMB 4,128,288,109.68 at the end of 2021[23]. - The total assets at the end of 2022 were CNY 4.93 billion, a decrease of 7.43% primarily due to a decline in the market value of holdings in Changjiang Securities[45]. - The company disposed of inefficient assets to improve overall asset quality, establishing a dedicated asset disposal task force[39]. - The company’s long-term equity investments increased to RMB 1,127.03 million in 2022, compared to RMB 1,080.90 million in 2021, marking an increase of about 4.3%[194]. Segment Performance - The pharmaceutical segment reported a consolidated operating revenue of 801.98 million RMB, down 8.13% year-on-year, with a net profit of 19.09 million RMB, up 35.12%[33]. - The property segment generated rental income of 75.43 million RMB, an increase of 5.32% year-on-year, and operating net profit of 49.11 million RMB, up 21.32%[35]. - The textile segment reported operating revenue of 231.94 million RMB, an increase of 13.31% year-on-year, but incurred a net loss of 9.03 million RMB due to restructuring costs[36]. - The company reported a net cash flow from operating activities of 33.56 million RMB in Q4 2022, indicating improved cash generation capabilities[27]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 0.45 per 10 shares, totaling RMB 54,317,551.14, which accounts for 33.11% of the net profit attributable to shareholders[6]. - The cash dividend per 10 shares is CNY 0.45, with no stock dividends or capital increases proposed[123]. - The company declared a cash dividend of CNY 54,317,551.14, which represents 33.11% of the net profit attributable to ordinary shareholders in the consolidated financial statements[123]. Risk Management - The company highlighted risks related to future development strategies and operational plans, advising investors to be cautious[9]. - The company faces market risks due to intense competition in its pharmaceutical and textile businesses, which could significantly impact performance[77]. - Regulatory risks from stricter environmental policies and changes in healthcare and real estate regulations may affect the company's operations[78]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, complying with legal requirements[85]. - The supervisory board is composed of 2 supervisors and 1 employee supervisor, adhering to legal standards[86]. - The company has established a performance evaluation and incentive mechanism linking senior management compensation to company and individual performance[87]. - The company has implemented an information disclosure management system to ensure timely and accurate information dissemination to shareholders[88]. Environmental Compliance - The company has implemented effective measures to ensure that all emissions are within the regulatory limits, demonstrating commitment to environmental compliance[135]. - The company has a wastewater treatment station with a daily capacity of 1,500 tons, which discharges treated water to an industrial wastewater treatment plant for further processing before discharge[140]. - The company reported no administrative penalties for environmental issues during the reporting period[144]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[96]. - The company is investing in R&D for new technologies, with an allocated budget of $50 million for the upcoming year[96]. - Market expansion plans include entering three new international markets by the end of 2024, aiming for a 10% market share in each[96].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 636.51 million, a decrease of 17.00% compared to CNY 766.92 million in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was CNY 125.22 million, representing an increase of 7.01% from CNY 117.01 million in the previous year[19]. - The basic earnings per share for the first half of 2022 was CNY 0.1037, up 7.02% from CNY 0.0969 in the same period last year[19]. - The weighted average return on equity increased to 2.99% from 2.75% year-on-year, reflecting a growth of 0.23 percentage points[19]. - The company reported a net profit of CNY 121.88 million after deducting non-recurring gains and losses, which is a 14.67% increase from CNY 106.30 million in the same period last year[19]. - The company achieved a total revenue of 636.51 million yuan, a year-on-year decrease of 17.00%, while net profit increased by 7.01% to 125.22 million yuan[27]. - The company reported a significant increase in other receivables, which rose to ¥97,431,316.00 from ¥28,733,212.38, a growth of approximately 238.5%[95]. - The company reported a net profit from its major subsidiaries, with Jiangxi Gannan Haixin Pharmaceuticals achieving a net profit of CNY 16,796,322.90[42]. Cash Flow and Assets - The net cash flow from operating activities decreased by 95.38%, down to CNY 10.39 million from CNY 225.01 million in the same period last year, primarily due to sales returns from the previous year's land sales[19]. - The company's cash and cash equivalents increased to ¥373,386,172.34 from ¥320,121,753.57, representing a growth of approximately 16.6%[95]. - Total current assets reached ¥1,061,400,732.96, up from ¥913,297,707.32, reflecting a growth of approximately 16.2%[95]. - Total assets decreased from CNY 5,325,619,470.52 to CNY 5,101,177,496.70, a decline of approximately 4.22%[96]. - The total assets of the company at the end of the reporting period were not explicitly stated but can be inferred from the equity figures provided[122]. Segment Performance - The pharmaceutical segment generated a combined revenue of 385.16 million yuan, down 10.27% year-on-year, but net profit rose significantly by 59.37% to 11.03 million yuan[27]. - The property leasing segment reported revenue of approximately 45.80 million yuan, an increase of 3.11% year-on-year, with net profit rising by 17.87% to 26.95 million yuan[29]. - The textile segment achieved revenue of 105.52 million yuan, a year-on-year increase of 10.31%, although it reported a net loss of 3.23 million yuan, worsening by 100.15% compared to the previous year[30]. Environmental Compliance - The company’s wastewater treatment facilities have consistently met discharge standards without exceeding limits for various pollutants[59]. - The company’s environmental compliance includes maintaining emissions below regulatory thresholds for volatile organic compounds and particulate matter[59]. - The company has implemented measures to ensure that all emissions are within regulatory limits, with most pollutants reported as not exceeding standards[60]. - The company has received an administrative penalty of 31,989 yuan for violating environmental impact assessment regulations in April 2022[70]. - The company operates under valid pollution discharge permits, with the latest for Baoding Changmaorong valid until January 16, 2026[66]. Governance and Management - The company has implemented measures to enhance management governance and optimize internal control systems to improve operational efficiency[32]. - The company experienced a change in senior management with the resignation of the vice president, Bao Sui[52]. - The company’s governance practices were reviewed and approved during the annual shareholder meeting held on June 23, 2022[50]. Strategic Initiatives - The company is actively pursuing the "G60 Zhejiang Science and Technology Base" project, with the goal of achieving the opening of the first phase by the end of the year[31]. - The company plans to continue focusing on market expansion and new product development to drive future growth[106]. Risks and Challenges - The company faces market risks due to intense competition in its pharmaceutical and textile businesses, which may significantly impact performance[44]. - Policy risks, including stricter environmental regulations and changes in healthcare policies, may affect the company's pharmaceutical manufacturing operations[45]. - The ongoing pandemic continues to introduce uncertainties in production and operations, impacting the macroeconomic and policy environment[47]. Financial Reporting and Accounting - The financial statements are prepared based on the enterprise accounting standards, reflecting the company's financial status and operating results accurately[131]. - The company recognizes expected credit losses for financial assets measured at amortized cost and those measured at fair value through other comprehensive income[157]. - The company measures expected credit losses for financial assets based on the present value of the difference between contractual cash flows received and expected cash flows[159]. - The company recognizes gains or losses from financial assets measured at fair value through profit or loss, unless they fall under specific exceptions[164].

Financial Performance - In 2021, the company achieved a total revenue of CNY 1,511,255,284.73, representing a 62.03% increase compared to CNY 932,727,985.27 in 2020[24]. - The net profit attributable to shareholders was CNY 132,091,780.53, which is a 10.64% increase from CNY 119,391,753.57 in the previous year[24]. - The net profit after deducting non-recurring gains and losses was CNY 103,858,333.22, reflecting a 14.69% increase from CNY 90,558,477.79 in 2020[24]. - The cash flow from operating activities increased by 79.31% to CNY 219,647,104.26, up from CNY 122,499,034.51 in 2020[24]. - The company achieved an operating revenue of 1.511 billion yuan in 2021, representing a year-on-year growth of 62.03%[33]. - The net profit for 2021 was 132 million yuan, an increase of 10.64% compared to the previous year[33]. - The weighted average return on equity rose to 3.12%, up from 2.98% in the previous year[28]. - The basic earnings per share increased to 0.1094 yuan, marking a growth of 10.62% year-on-year[28]. Segment Performance - The pharmaceutical segment generated revenue of 872.99 million yuan, a year-on-year increase of 36.35%[34]. - The revenue from the Gannan Haixin segment reached 595.90 million yuan, growing by 81.72% year-on-year[34]. - The property segment achieved rental income of 71.62 million yuan, reflecting an 18.24% increase from the previous year[35]. - The textile segment accelerated its adjustment, achieving revenue of 204.7 million yuan, a year-on-year decrease of 11.54%, with a consolidated net loss of 3.87 million yuan, improving by 32.44 million yuan year-on-year[36]. - The pharmaceutical manufacturing and sales segment generated a consolidated revenue of 872.99 million RMB, up 36.35% year-on-year, with a net profit of 14.13 million RMB[48]. - The property management segment achieved rental income of 71.62 million RMB, a growth of 18.24% year-on-year, with a net profit of 40.48 million RMB[48]. Assets and Liabilities - As of the end of 2021, the total assets amounted to CNY 5,325,619,470.52, a decrease of 5.32% from CNY 5,625,066,071.47 at the end of 2020[24]. - The company's net assets attributable to shareholders were CNY 4,128,288,109.68, showing a slight decrease of 1.45% from CNY 4,189,071,328.66 in 2020[24]. - The company had a total asset value of 5.326 billion RMB at the end of 2021, a decrease of 5.32% year-on-year, primarily due to a decline in the market value of Changjiang Securities[48]. - The company holds overseas assets valued at RMB 92.91 million, which constitutes 1.74% of total assets[70]. Cash Flow and Investments - The cash flow from investment income increased by 30.34% to ¥122,034,892.62, reflecting higher dividends received compared to the previous year[66]. - The company's investment activities resulted in a net cash outflow of 64.16 million RMB, while financing activities saw a net cash outflow of 231.25 million RMB, a significant increase of 317.58% year-on-year[49]. - The company achieved a revenue of 6.74 million yuan from financial investments, including activities related to Jiangsu Securities stocks and new stock subscriptions[40]. - The company has significant investments in structured deposits, with a total initial investment of RMB 240.50 million and a year-end book value of RMB 240.50 million, resulting in a report period profit of RMB 5.58 million[73]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, and operates under established rules to ensure effective governance[97]. - The supervisory board is composed of 2 supervisors and 1 employee supervisor, adhering to legal requirements and effectively overseeing financial compliance[98]. - The company has established a performance evaluation and incentive mechanism linking senior management compensation to company and individual performance[99]. - The company has implemented an information disclosure management system to ensure timely and accurate information dissemination to all shareholders[100]. - The company has established four specialized committees under the board to enhance decision-making efficiency and governance[97]. Risk Management - The company has outlined potential risks in its future development strategies, which investors should be aware of[11]. - The company faces market risks due to intense competition in its pharmaceutical and textile sectors, which could significantly impact performance[88]. - Regulatory risks from stricter environmental policies and changes in healthcare regulations may affect the company's operations in the pharmaceutical and textile sectors[89]. - The company has a structured approach to risk management and compliance, with key personnel holding multiple roles in financial and asset management sectors[115]. Environmental Compliance - The company has successfully maintained ammonia emissions below 4.9 kg/h, adhering to the standards set by GB14554-93[146]. - The concentration of particulate matter from the exhaust is controlled to be less than 120 mg/Nm3, ensuring compliance with air pollution standards[146]. - The wastewater treatment process has a biochemical oxygen demand (BOD) limit of ≤500 mg/L, which is consistently met[146]. - The company reported that the concentration of sulfur dioxide emissions from boiler exhaust is maintained below 300 mg/Nm3, complying with GB13271-2014 standards[145]. - The company has reported no exceedances in the emission limits for all monitored pollutants, demonstrating effective environmental management practices[146]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 63,932, an increase from 63,644 in the previous month[178]. - The largest shareholder, Shenzhen Ningrui Investment Management, holds 141,528,801 shares, representing 11.73% of the total shares[180]. - The second-largest shareholder, Shanghai Songjiang Dongjing Industrial Company, holds 82,082,000 shares, accounting for 6.80%[180]. - The company has not reported any changes in its total share capital or share structure during the reporting period[176]. Strategic Focus - The company plans to continue expanding its market presence and enhancing product quality in response to changing economic conditions and consumer demands[33]. - The company is focusing on strategic planning for the "14th Five-Year Plan," emphasizing revitalizing existing assets and strengthening core businesses, particularly in the pharmaceutical and property sectors[41]. - The company aims to implement a "large property and asset management" model, transitioning from basic property leasing to comprehensive property services and asset management[84]. - The strategic focus includes leveraging new emerging industries and aligning with national policies to support sustainable development and transformation[83].

Financial Performance - The company's operating revenue for Q3 2021 was ¥328,490,601.12, representing a year-on-year increase of 5.80%[3] - The net profit attributable to shareholders for the same period was ¥32,406,549.88, up 12.01% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached ¥32,371,493.52, reflecting an 18.12% increase year-on-year[3] - Total operating revenue for the first three quarters of 2021 reached ¥1,095,415,385.72, a significant increase from ¥738,457,035.94 in the same period of 2020, representing a growth of approximately 48.5%[15] - Net profit for the first three quarters of 2021 was ¥153,679,362.35, up from ¥116,164,146.80 in 2020, reflecting a growth of approximately 32.3%[16] - Earnings per share for the first three quarters of 2021 were ¥0.1238, compared to ¥0.1001 in the same period of 2020, marking an increase of about 23.7%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥221,925,345.73, showing a significant increase of 307.39%[3] - Cash flow from operating activities for the first three quarters of 2021 was ¥1,134,547,722.96, compared to ¥841,174,931.61 in 2020, showing an increase of approximately 34.8%[18] - Net cash inflow from operating activities was $221,925,345.73, a significant increase compared to $54,474,582.46 in the previous year, representing a growth of approximately 307%[19] - Total cash outflow for operating activities was $976,767,046.66, an increase from $870,838,760.49, reflecting a rise of approximately 12%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,426,924,104.70, a decrease of 3.52% from the end of the previous year[4] - The company's total assets amounted to ¥5,426,924,104.70 as of the end of the third quarter of 2021, down from ¥5,625,066,071.47 at the end of the same period in 2020[14] - The company's current assets totaled ¥965,646,711.95, an increase from ¥834,890,087.59 in the previous year[12] - The company's total liabilities decreased to ¥1,069,305,893.56 from ¥1,245,567,071.88, reflecting a reduction of about 14.2%[13] - The non-current assets were reported at ¥4,461,277,392.75, down from ¥4,790,175,983.88, showing a decline of approximately 6.9%[12] - The company's equity remained stable at ¥1,207,056,692.00, unchanged from the previous year[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 62,591, with 29,693 A-share and 32,898 B-share holders[8] - The top shareholder, Shenzhen Ningrui Investment Management Enterprise, held 141,528,801 shares, accounting for 11.73% of the total shares[8] Project Performance - The company reported a significant increase in revenue from the Haixin Zhihui project, contributing ¥202 million to the total revenue[6] - The net profit from the Haixin Zhihui project delivery was ¥14.0862 million, contributing positively to the overall profit[6] Research and Development - Research and development expenses for the first three quarters of 2021 were ¥14,528,317.02, compared to ¥13,196,580.82 in 2020, indicating an increase of about 10.1%[15] Investment Income - The company reported investment income of ¥134,915,654.85 for the first three quarters of 2021, compared to ¥127,823,448.66 in 2020, reflecting a growth of approximately 5.5%[16]